Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Global Anomaly Detection Market is projected to reach USD 19.4 Billion by 2031

    80% confidence
  • North America maintains dominance within the anomaly detection market, supported by advanced cybersecurity infrastructure, high enterprise digitalization levels, and early adoption of AI-driven analytics solutions

    80% confidence
  • The Global Anomaly Detection Market was valued at USD 5.66 Billion in 2024

    80% confidence
  • Market expansion is attributed to growing enterprise investments in AI-enabled monitoring systems, expanding application across digital security frameworks, and accelerating demand for automated threat detection solutions

    80% confidence
  • The market will expand at a CAGR of 16.65% during the forecast period from 2024 to 2031

    80% confidence
  • Strict regulatory frameworks governing data usage impose operational challenges for anomaly detection vendors and enterprise adopters

    80% confidence
  • Many enterprises face technical and financial constraints when integrating anomaly detection solutions into fragmented legacy systems

    80% confidence
  • Asia-Pacific is emerging as a high-growth region, fueled by digital transformation, rising cyber risks, and expanding cloud adoption

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com